



## Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company's proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for chronic spinal cord injury (SCI). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product.

Driven by more than 20 years of pioneering research and innovation, StemCells, Inc. is the undisputed leader in human neural stem cell research and development. As the first ever to conduct a U.S. clinical trial with human neural stem cells, StemCells is the only company, to date, with established human safety and preliminary efficacy data for these cells. The Company's comprehensive patent portfolio includes seminal technology in cell biology, with neural stem cell patents covering compositions of matter, methods of manufacture and methods of use. Credited with significant breakthroughs in the field, the StemCells team includes internationally renowned experts in stem cell biology, biotechnology, regenerative medicine and cGMP manufacturing.

Learn more about [What Sets Us Apart](#).


## Primary IR Contact

Greg Schiffman  
CFO  
Stem Cells, Inc.  
**Phone:** (510) 456-4128  
**Fax:** (510) 456-4001  
**E-mail:** [irpr@stemcellsinc.com](mailto:irpr@stemcellsinc.com)

## Stock Performance

STEM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$6.40</b>
Change (%)	<b>▼ 0.27 (4.05%)</b>
Volume	70,704
52 Week Low	\$2.97
Market Cap	\$0
Rolling EPS	-18.18
PE Ratio	N/A
Shares Outstanding	0

Data as of 12/30/16 4:00 p.m. ET




## Recent Headlines & Events

There are currently no events scheduled.

## Analyst Estimates / Ratings

Mean Recommendation: 2.0



### EPS Trend

	Current	30 Days Ago	90 Days Ago
QTR			
QTR			
QTR			
QTR			
FY			
FY			

## SEC Filings

### Year Filter

All Years

Filing Date	Form
11/14/17	10-Q
11/08/17	8-K
10/30/17	S-8
10/26/17	SC 13D/A

## Corporate Governance

Ken Stratton      President and General Counsel

## Ownership Summary

### Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	47	37.98	64.2	24,801,721
Mutual Fund	11	.46	1.0	370,474
Insider *	6	53.95	28.0	10,789,645

\*Insider values reflect direct beneficial ownership.

### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Bornstein (Yoseph)	4,880,399	12.6	-425,010	10/24/17
Berkson (Avram)	4,307,003	11.2	0	06/08/17
Technion Research & Development Foundation Ltd (TRDF)	3,555,339	9.2	0	08/06/17
MEDX Ventures Group LLC	2,652,704	6.9	0	08/06/17
GreenBlock Capital, L.L.C.	1,753,091	4.5	-197,569	08/06/17
Lewkowicz (Leon)	1,566,020	4.1	-752,532	07/12/17
Shoham (Moshe)	1,558,390	4.0	-33,700	10/09/17
Lane Ventures, Inc	1,412,150	3.7	-538,510	08/09/17
Alpha Capital Aktiengesellschaft	1,299,476	3.4	1,294,846	11/29/16
Sabby Management, LLC	1,251,398	3.2	-33,953	09/30/17

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed